These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 30514381)

  • 1. The association between early-onset cardiac events caused by neoadjuvant or adjuvant chemotherapy in triple-negative breast cancer patients and some novel autophagy-related polymorphisms in their genomic DNA: a real-world study.
    Liu B; An T; Li M; Yi Z; Li C; Sun X; Guan X; Li L; Wang Y; Zhang Y; Xu B; Ma F; Zeng Y
    Cancer Commun (Lond); 2018 Dec; 38(1):71. PubMed ID: 30514381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy.
    Li M; Ma F; Wang J; Li Q; Zhang P; Yuan P; Luo Y; Cai R; Fan Y; Chen S; Li Q; Xu B
    Chin J Cancer; 2018 Jan; 37(1):4. PubMed ID: 29382381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.
    Clifton K; Gutierrez-Barrera A; Ma J; Bassett R; Litton J; Kuerer H; Moulder S; Albarracin C; Hortobagyi G; Arun B
    Breast Cancer Res Treat; 2018 Jul; 170(1):101-109. PubMed ID: 29470805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients.
    Vulsteke C; Pfeil AM; Maggen C; Schwenkglenks M; Pettengell R; Szucs TD; Lambrechts D; Dieudonné AS; Hatse S; Neven P; Paridaens R; Wildiers H
    Breast Cancer Res Treat; 2015 Jul; 152(1):67-76. PubMed ID: 26017071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.
    Gamucci T; Pizzuti L; Sperduti I; Mentuccia L; Vaccaro A; Moscetti L; Marchetti P; Carbognin L; Michelotti A; Iezzi L; Cassano A; Grassadonia A; Astone A; Botticelli A; Magnolfi E; Di Lauro L; Sergi D; Fuso P; Tinari N; Barba M; Maugeri-Saccà M; Landucci E; Conti F; Sanguineti G; De Tursi M; Iafrate G; Giordano A; Ciliberto G; Natoli C; Vici P
    J Cell Physiol; 2018 Mar; 233(3):2313-2323. PubMed ID: 28710865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of UGT2B7 Polymorphism with Cardiotoxicity in Breast Cancer Patients Undergoing Epirubicin/Cyclophosphamide-Docetaxel Adjuvant Chemotherapy.
    Li H; Hu B; Guo Z; Jiang X; Su X; Zhang X
    Yonsei Med J; 2019 Jan; 60(1):30-37. PubMed ID: 30554488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and genetic predictions of early-onset cardiac toxicity in adjuvant chemotherapy for breast cancer.
    Liu B; Guan X; Wang Y; Sun X; Yi Z; Lv D; Wang W; Li L; Zhai J; Li H; Ma F
    Future Oncol; 2022 Jun; 18(17):2127-2139. PubMed ID: 35414207
    [No Abstract]   [Full Text] [Related]  

  • 8. Polymorphisms rs4673 and rs28714259 in predicting anthracycline-mediated cardiotoxicity in patients with breast cancer.
    Gvaldin GD; Timoshkina TN; Vladimirova L; Svetitskaya SY; Vaschenko VL
    Klin Onkol; 2021; 34(6):463-466. PubMed ID: 34911332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
    Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single Nucleotide Polymorphisms (SNPs) of RAD51-G172T and XRCC2-41657C/T Homologous Recombination Repair Genes and the Risk of Triple- Negative Breast Cancer in Polish Women.
    Michalska MM; Samulak D; Romanowicz H; Smolarz B
    Pathol Oncol Res; 2015 Sep; 21(4):935-40. PubMed ID: 25743260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.
    Gavila J; Seguí MÁ; Calvo L; López T; Alonso JJ; Farto M; Sánchez-de la Rosa R
    Clin Transl Oncol; 2017 Jan; 19(1):91-104. PubMed ID: 27101413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete Metabolic Response on Interim
    Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
    Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.
    Absmaier M; Napieralski R; Schuster T; Aubele M; Walch A; Magdolen V; Dorn J; Gross E; Harbeck N; Noske A; Kiechle M; Schmitt M
    Int J Oncol; 2018 Mar; 52(3):755-767. PubMed ID: 29328369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
    Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
    Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer.
    Ren YX; Hao S; Jin X; Ye FG; Gong Y; Jiang YZ; Shao ZM
    Breast; 2019 Feb; 43():97-104. PubMed ID: 30529406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
    Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
    Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.
    Sági JC; Egyed B; Kelemen A; Kutszegi N; Hegyi M; Gézsi A; Herlitschke MA; Rzepiel A; Fodor LE; Ottóffy G; Kovács GT; Erdélyi DJ; Szalai C; Semsei ÁF
    BMC Cancer; 2018 Jul; 18(1):704. PubMed ID: 29970035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
    de Nonneville A; Gonçalves A; Zemmour C; Cohen M; Classe JM; Reyal F; Colombo PE; Jouve E; Giard S; Barranger E; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
    Eur J Cancer; 2017 Oct; 84():34-43. PubMed ID: 28780480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Neoadjuvant
    Philipovskiy A; Corral J; Dwivedi KA; Heydarian R; Gaur S
    In Vivo; 2019; 33(4):1227-1234. PubMed ID: 31280213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular volume measured by whole body CT scans predicts chronic cardiotoxicity in breast cancer patients treated with neoadjuvant therapies based on anthracyclines: A retrospective study.
    Rosenfeld R; Riondino S; Cerocchi M; Luciano A; Idone G; Lecis D; Illuminato F; Tolomei A; Torino F; Chiocchi M; Roselli M
    Breast; 2024 Aug; 76():103755. PubMed ID: 38852211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.